AstraZeneca PLC (LON:AZN) is set to hear the EU regulator’s decision on the COVID-19 vaccine developed with Oxford University later today.
Experts from the European Medicines Agency (EMA) are discussing whether to keep rolling out the jab in the bloc after there were cases of blood clots in people who had received it.
Austria, Bulgaria, Cyprus, Denmark, Estonia, France, Germany, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Portugal, Slovenia, Spain and Sweden have currently halted the rollout of the inoculation or banned certain batches.
Iceland and Norway, which aren’t part of the EU, have also suspended its use.
However until now, the UK and the EMA invited residents to continue get the jab when asked to do so.
Similarly, the World Health Organization (WHO) said on Wednesday the benefits of the vaccine outweigh its risks, so it recommended that rollouts continue while investigations are ongoing.
On Sunday, the FTSE 100 pharma giant said that a review of all available safety data of the 17mln people who have received the jab in the EU and UK has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia.
So far across the EU and UK, there have been 15 events of DVT and 22 events of pulmonary embolism reported among those given the vaccine.
But the Anglo-Swedish firm said the number is “much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines”.
Shares in AstraZeneca were flat at 7,111p on Thursday ahead of the verdict.